Skip to main content
Egyptian Rheumatology and Rehabilitation

Table 4 aPLs in different types of thrombosis in COVID-19 patients (n = 65)

From: Anti-phospholipid antibodies in the setting of thromboembolic events associated with severe COVID-19 pneumonia

Positive aPLs

DVT + PE

3 (4.6%)

PE

48(73.8%)

DVT

2(3.1%)

Stroke

6(9.2%)

Limb

ischemia

1 (1.5%)

MI

2(3.1%)

RAT

1(1.5%)

Bowel ischemia

2 (3.1%)

LAC

1(33.3)

16(33.3)

2(100)

5(83.3)

1(100)

2(100)

1(100)

2(100)

aCL IgG

aCL IgM

0(0)

0(0)

5(10.4)

3(6.3)

0(0)

0(0)

2(33.3)

1(16.7)

0(0)

0(0)

1(50)

0(0)

1(100)

0(0)

1(50)

0(0)

aβ2GPI gG

aβ2GPI gM

0(0)

0(0)

6(12.5) 1(2.1)

1(50)

0(0)

2(33.3)

2(33.3)

0(0)

0(0)

1(50)

1(50)

1(100)

0(0)

1(50)

0(0)

  1. aPLs anti-phospholipid antibodies, LAC lupus anti-coagulant, aCL anti-cardiolipin, aβ2GPI anti-β2 glycoprotein, MI myocardial infarction, RAT renal artery thrombosis, data are expressed as no. (%)
Back to article page